Fosigotifator by Calico Life Sciences for Unspecified Central Nervous System Disorders: Likelihood of Approval

Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.

Defender’s plans for motion sickness nasal gel stop with FDA rejection – Pharmaceutical Technology

Share this article Nasa is helping with Defender’s development of DPI-386, as astronauts are particularly susceptible to motion sickness in space. Image credit: Shutterstock/Supamotionstock.com. The

January 31, 2024

Can strawberries mitigate Alzheimer’s risk? Recent study suggests a possibility

Whether strawberry supplementation mitigates the risk for late-life dementia.

October 23, 2023

House Republicans abandon PBM reform in push to keep government open

WASHINGTON — House Republicans have abandoned an effort to include reforms to pharmacy benefit managers in an end-of-year bill to fund the federal government. Congressional leaders

December 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.